129 pending office actions • 32 clients
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 19346623 | Untitled | Merck Sharp & Dohme LLC | BALLARD, KIMBERLY | 1675 | Non-Final OA | |
| 19346638 | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF | Merck Sharp & Dohme LLC | BALLARD, KIMBERLY | 1675 | Non-Final OA | Oct 01, 2025 |
| 19346648 | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF | Merck Sharp & Dohme LLC | GODDARD, LAURA B | 1642 | Non-Final OA | Oct 01, 2025 |
| 19040427 | DETERMINING THE LOCATION OF AN ANIMAL | Allflex Australia Pty Ltd. | KHAN, OMER S | 2686 | Non-Final OA | Jan 29, 2025 |
| 18969544 | ELECTRONIC ANIMAL TAG READER | Allflex Australia Pty Ltd. | MORTELL, JOHN F | 2689 | Non-Final OA | Dec 05, 2024 |
| 18721438 | IMPROVEMENTS IN ELECTRONIC IDENTIFICATION TAG READER SYSTEMS | Allflex Australia Pty. Ltd. | ALUNKAL, THOMAS D | 2686 | Non-Final OA | Jun 18, 2024 |
| 18710007 | AMPOULE FOR ORAL VACCINE ADMINISTRATION AND METHODS OF USE | Merck Sharp & Dohme LLC | WENG, KAI H | 3781 | Non-Final OA | May 14, 2024 |
| 18708248 | A METHOD TO PRODUCE A VACCINE AGAINST STREPTOCOCCUS SUIS AND THE SAID VACCINE | Intervet Inc. | DEVI, SARVAMANGALA | 1645 | Non-Final OA | May 08, 2024 |
| 18625385 | STREPTOCOCCUS PNEUMONIAE SEROTYPE-SPECIFIC DETECTION ASSAY, REAGENTS AND KITS | Merck Sharp & Dohme LLC | OGUNBIYI, OLUWATOSIN A | 1645 | Non-Final OA | Apr 03, 2024 |
| 18689149 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | Merck Sharp & Dohme LLC | SHTERENGARTS, SAMANTHA L | 1623 | Non-Final OA | Mar 05, 2024 |
| 18689148 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | Merck Sharp & Dohme LLC | STOCKTON, LAURA LYNNE | 1626 | Non-Final OA | Mar 05, 2024 |
| 18685357 | C-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC | ULLMAN, AARON RAFANAN | 1628 | Non-Final OA | Feb 21, 2024 |
| 18293380 | A VACCINE FOR PROTECTION AGAINST STREPTOCOCCUS SUIS OF VARIOUS SEROTYPES | Intervet Inc. | OGUNBIYI, OLUWATOSIN A | 1645 | Non-Final OA | Jan 30, 2024 |
| 18293007 | A VACCINE FOR PROTECTION AGAINST STREPTOCOCCUS SUIS OF VARIOUS SEROTYPES | Intervet Inc. | DUFFY, PATRICIA ANN | 1645 | Non-Final OA | Jan 29, 2024 |
| 18577775 | METHOD FOR ANALYZING TRACE LEVELS OF SEMI-VOLATILE NITROSAMINES IN SOLID SAMPLES | Merck Sharp & Dohme LLC | SINGER, DAVID L | 2855 | Non-Final OA | Jan 09, 2024 |
| 18570341 | METHOD AND SYSTEM FOR COUNTING BIRD PARASITES | Intervet Inc. | MUKUNDHAN, ROHAN TEJAS | 2663 | Non-Final OA | Dec 14, 2023 |
| 18524612 | PREPARATION OF FUSED AZOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE 0-ACYLTRANSFERASE 2 INHIBITORS | Merck Sharp & Dohme LLC | BAUER, NICOLA MARIA | 1621 | Non-Final OA | Nov 30, 2023 |
| 18563157 | TRANSAMINASE ENZYMES FOR THE TRANSAMINATION OF (1S,5R)-6,8-DIOXABICYCLO[3.2.1]OCTAN-4-ONE | Merck Sharp & Dohme LLC | HUTSON, RICHARD G | 1652 | Non-Final OA | Nov 21, 2023 |
| 18563082 | SYNTHESIS OF BTK INHIBITOR AND INTERMEDIATES THEREOF | Merck Sharp & Dohme LLC | FETTEROLF, BRANDON J | 1626 | Non-Final OA | Nov 21, 2023 |
| 18513791 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | Merck Sharp & Dohme LLC | VARADARAJ, ARCHANA | 1658 | Non-Final OA | Nov 20, 2023 |
| 18556226 | PHENYL AZEPINES AS RIPK1 INHIBITORS AND METHODS OF USE THEREOF | Merck Sharp & Dohme LLC | MARTIN, KEVIN STEPHEN | 1624 | Non-Final OA | Oct 19, 2023 |
| 18556222 | RIPK1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC | HEASLEY, MEGHAN CHRISTINE | 1626 | Non-Final OA | Oct 19, 2023 |
| 18556196 | IL4I1 INHIBITORS AND METHODS OF USE | Msd R&D (China) Co., Ltd. | HSU, GRACE CHING | 1627 | Non-Final OA | Oct 19, 2023 |
| 18484485 | BLOW-FILL SEALING METHOD FOR FILLING AND PACKAGING | Merck Sharp & Dohme LLC | LUK, EMMANUEL S | 1744 | Non-Final OA | Oct 11, 2023 |
| 18554472 | AN ANIMAL TAG APPLICATOR | Allflex Europe SAS | MCEVOY, THOMAS M | 3771 | Final Rejection | Oct 08, 2023 |
| 18554213 | METHODS FOR TREATING CANCER WITH SUBCUTANEOUS ADMINISTRATION OF ANTI-PD1 ANTIBODIES | Merck Sharp & Dohme LLC | STEPHENS, AMELIA CAROLE | 1645 | Non-Final OA | Oct 06, 2023 |
| 18553774 | NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS | Merck Sharp & Dohme LLC | VANHORN, ABIGAIL LOUISE | 1636 | Non-Final OA | Oct 03, 2023 |
| 18550537 | METHODS FOR TREATING CANCER WITH ANTI-ILT3 ANTIBODIES | Merck Sharp & Dohme LLC | JOHANSEN, PETER N. | 1644 | Non-Final OA | Sep 14, 2023 |
| 18550348 | A CLOSED-SYSTEM UPSTREAM MANUFACTURING PROCESS FOR DENGUE VIRUS PRODUCTION | Merck Sharp & Dohme LLC | TANG, JIANMING | 1671 | Non-Final OA | Sep 13, 2023 |
| 18550332 | PLASMA KALLIKREIN INHIBITORS | Merck Sharp & Dohme LLC | JARRELL, NOBLE E | 1699 | Non-Final OA | Sep 13, 2023 |
| 18549461 | ACTRII-ALK4 ANTAGONISTS AND METHODS OF TREATING HEART FAILURE | Acceleron Pharma, Inc. | HADDAD, MAHER M | 1641 | Non-Final OA | Sep 07, 2023 |
| 18549474 | ACTRII-ALK4 ANTAGONISTS AND METHODS OF TREATING HEART FAILURE | Acceleron Pharma, Inc. | BERHANE, SELAM | 1675 | Non-Final OA | Sep 07, 2023 |
| 18548640 | REDUCING HIGH MANNOSE GLYCAN PROTEIN EXPRESSION USING GUANOSINE 5'-MONOPHOSPHATE | Merck Sharp & Dohme LLC | HOLLAND, PAUL J | 1656 | Non-Final OA | Sep 01, 2023 |
| 18457177 | COMBINATION THERAPY WITH IMMUNE CELL ENGAGING PROTEINS AND IMMUNOMODULATORS | Harpoon Therapeutics, Inc. | HADDAD, MAHER M | 1641 | Non-Final OA | Aug 28, 2023 |
| 18236082 | TGF-BETA SUPERFAMILY TYPE I AND TYPE II RECEPTOR HETEROMULTIMERS AND USES THEREOF | Acceleron Pharma, Inc. | LI, RUIXIANG | 1674 | Non-Final OA | Aug 21, 2023 |
| 18546955 | ANTI-CD30L ANTIBODIES AND USES THEREOF | Dr. Falk Pharma GmbH | BELYAVSKYI, MICHAIL A | 1644 | Non-Final OA | Aug 17, 2023 |
| 18264940 | PANCREAS TARGETED THERAPEUTICS AND USES THEREOF | Pandion Operations, Inc. | LU, CHENG | 1642 | Non-Final OA | Aug 10, 2023 |
| 18366876 | PROTEINS BINDING NKG2D, CD16, AND CEACAM5 | Dragonfly Therapeutics, Inc. | PRIEST, JESSICA MARIE | 1642 | Non-Final OA | Aug 08, 2023 |
| 18264586 | SYNTHESIS OF URIDINE | Merck Sharp & Dohme LLC | WARD, PAUL V | 1622 | Non-Final OA | Aug 08, 2023 |
| 18264468 | ARYL ETHER COMPOUNDS AS TEAD MODULATORS | Merck Sharp& Dohme LLC | O DELL, DAVID K | 1621 | Non-Final OA | Aug 07, 2023 |
| 18264330 | VACCINE FOR MYCOPLASMA BOVIS | Atg: Biosynthetics GmbH | OGUNBIYI, OLUWATOSIN A | 1645 | Non-Final OA | Aug 04, 2023 |
| 18263551 | CHEMOVACCINATION AGAINST PLASMODIUM INFECTION WITH SELECTIVE PLASMEPSIN X INHIBITORS | The Walter and Eliza Hall Institute of Medical Research | FETTEROLF, BRANDON J | 1626 | Non-Final OA | Jul 31, 2023 |
| 18263289 | NANOEMULSION ADJUVANT COMPOSITION FOR PNEUMOCOCCAL CONJUGATE VACCINES | Merck Sharp & Dohme LLC | LYONS, MARY M | 1645 | Non-Final OA | Jul 27, 2023 |
| 18263227 | CYCLOPROPYLAMIDE COMPOUNDS AGAINST PARASITES IN FISH | Corteva Agriscience LLC | PATEL, SAGAR S | 1626 | Non-Final OA | Jul 27, 2023 |
| 18263277 | LIPID NANOPARTICLE ADJUVANT COMPOSITION FOR PNEUMOCOCCAL CONJUGATE VACCINES | Merck Sharp & Dohme LLC | MORGAN, BAILEY MICHELLE | 1645 | Non-Final OA | Jul 27, 2023 |
| 18263211 | ANTIPARASITIC COMPOUNDS | Intervet Inc. | SZNAIDMAN, MARCOS L | 1628 | Non-Final OA | Jul 27, 2023 |
| 18260670 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | Caraway Therapeutics, Inc. | TOWNSLEY, SARA ELIZABETH | 1629 | Non-Final OA | Jul 07, 2023 |
| 18348787 | DENSIFIED CO-PRECIPITATED MATERIALS ISOLATED BY THIN FILM EVAPORATION | Merck Sharp & Dohme LLC | GOTFREDSON, GAREN | 1619 | Non-Final OA | Jul 07, 2023 |
| 18346315 | NOVEL SYNTHETIC PATHWAY TO BELZUTIFAN | Merck Sharp & Dohme LLC | SWIFT, CANDICE LEE | 1657 | Non-Final OA | Jul 03, 2023 |
| 18258397 | IL-2 MUTEINS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES | Merck Sharp & Dohme LLC | GURLEY, JAMI MICHELLE | 1647 | Non-Final OA | Jun 20, 2023 |
| 18335415 | SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR ISOXAZOLINE COMPOUNDS | Intervet Inc. | BORALSKY, LUKE ALAN | 1624 | Non-Final OA | Jun 15, 2023 |
| 18257600 | CONJUGATED AFLATOXIN B TO PROTECT AGAINST MYCOTOXICOSIS | Intervet Inc. | KIM, YUNSOO | 1641 | Non-Final OA | Jun 15, 2023 |
| 18257334 | ENTEROVIRUS PURIFICATION WITH CATION EXCHANGE CHROMATOGRAPHY | Andrew Ryan Swartz | JADHAO, SAMADHAN JAISING | 1672 | Non-Final OA | Jun 14, 2023 |
| 18257409 | CONJUGATED FUMONISIN TO PROTECT AGAINST MYCOTOXICOSIS | Intervet Inc. | TAYLOR, LIA ELAN | 1641 | Non-Final OA | Jun 14, 2023 |
| 18257420 | CONJUGATED T-2 TOXIN TO PROTECT AGAINST MYCOTOXICOSIS | Intervet Inc. | MORGAN, BAILEY MICHELLE | 1645 | Non-Final OA | Jun 14, 2023 |
| 18256997 | FUSED BICYCLIC PYRAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | Merck Sharp & Dohme LLC | JOHNSON, CHRISTOPHER LINDSAY | 1691 | Final Rejection | Jun 12, 2023 |
| 18256943 | MINI-TABLET DOSAGE FORM OF A VIRAL TERMINASE INHIBITOR AND USES THEREOF | Merck Sharp & Dohme LLC | KASSA, TIGABU | 1619 | Non-Final OA | Jun 12, 2023 |
| 18254898 | LIPID NANOPARTICLE COMPOSITIONS CONTAINING MONOESTER CATIONIC LIPIDS | Merck Sharp & Dohme LLC | LIPPERT, JOHN WILLIAM | 1615 | Final Rejection | May 30, 2023 |
| 18254401 | A METHOD OF TREATING FOOT ROT | Intervet Inc. | SCHACHERMEYER, SAMANTHA LYNN | 1693 | Final Rejection | May 25, 2023 |
| 18252624 | RECOMBINANT VECTORS ENCODING CHIMERIC CORONAVIRUS SPIKE PROTEINS AND USE THEREOF | Intervet Inc. | SIFFORD, JEFFREY MARK | 1671 | Non-Final OA | May 11, 2023 |
| 18252217 | 3-AMINO PYRROLIDINE AND PIPERIDINE MACROCYCLIC OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC | COLEMAN, BRENDA LIBBY | 1624 | Final Rejection | May 09, 2023 |
| 18252081 | MADCAM TARGETED THERAPEUTICS AND USES THEREOF | Pandion Operations, Inc. | LU, CHENG | 1642 | Non-Final OA | May 08, 2023 |
| 18252007 | EPCAM TARGETING TRISPECIFIC PROTEIN FOR TREATMENT OF CANCER | Harpoon Therapeutics, Inc. | MERTZ, PREMA MARIA | 1674 | Non-Final OA | May 05, 2023 |
| 18251314 | ANTI-RESPIRATORY SYNCYTIAL VIRUS (RSV) ANTIBODY CELL-BASED POTENCY ASSAY | Merck Sharp & Dohme LLC | BURKHART, MICHAEL D | 1638 | Non-Final OA | May 01, 2023 |
| 18251259 | DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1 | Merck Sharp & Dohme LLC | WHITE, DAWANNA SHAR-DAY | 1627 | Final Rejection | May 01, 2023 |
| 18250404 | METHODS FOR TREATING HEMATOLOGIC MALIGNANCIES WITH AMINO-PYRROLOPYRIMIDINONE COMPOUNDS | Merck Sharp & Dohme LLC | OTTON, ALICIA L | 1699 | Non-Final OA | Apr 25, 2023 |
| 18250106 | COMBINATION VACCINE FOR PROTECTING SWINE AGAINST VARIOUS DISORDERS | Intervet Inc. | SZPERKA, MICHAEL EDWARD | 1641 | Non-Final OA | Apr 21, 2023 |
| 18249419 | BACULOVIRUS EXPRESSION VECTOR | Intervet Inc. | JADHAO, SAMADHAN JAISING | 1672 | Non-Final OA | Apr 18, 2023 |
| 18248398 | KIDNEY TARGETED IMMUNOTOLERANCE | Pandion Operations, Inc. | MERTZ, PREMA MARIA | 1674 | Non-Final OA | Apr 10, 2023 |
| 18188578 | PHARMACEUTICAL FORMULATIONS FOR TREATING DISEASES MEDIATED BY KDM1A | Imago Biosciences, Inc. | CHANDRAKUMAR, NIZAL S | 1625 | Non-Final OA | Mar 23, 2023 |
| 18246467 | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND HYALURONIDASE VARIANTS AND FRAGMENTS THEREOF AND METHODS OF USE THEREOF | Merck Sharp & Dohme LLC | CHHAY, BONIRATH | 1645 | Non-Final OA | Mar 23, 2023 |
| 18246408 | CORONAVIRUS REPLICONS FOR ANTIVIRAL SCREENING AND TESTING | Merck Sharp & Dohme LLC | KONOPKA, CATHERINE ANNE | 1635 | Non-Final OA | Mar 23, 2023 |
| 18188037 | SINGLE CHAIN VARIABLE FRAGMENT CD3 BINDING PROTEINS | Harpoon Therapeutics, Inc. | SKELDING, ZACHARY S | 1644 | Non-Final OA | Mar 22, 2023 |
| 18245563 | BINDING PROTEINS AND ANTIGEN BINDING FRAGMENTS THEREOF THAT BIND ABETA | Merck Sharpe & Dohme LLC | ALLEN, MARIANNE P | 1647 | Non-Final OA | Mar 16, 2023 |
| 18245590 | DOSING REGIMENS OF ANTI-ILT4 ANTIBODY OR ITS COMBINATION WITH ANTI-PD-1 ANTIBODY FOR TREATING CANCER | Merck Sharp & Dohme LLC | LANDSMAN, ROBERT S | 1647 | Non-Final OA | Mar 16, 2023 |
| 18184392 | MESOTHELIN BINDING PROTEINS | Harpoon Therapeutics, Inc. | MOSELEY II, NELSON B | 1642 | Non-Final OA | Mar 15, 2023 |
| 18043357 | PLASMA KALLIKREIN INHIBITORS | Merck Sharp & Dohme LLC | HERNANDEZ, JACKSON J | 1627 | Final Rejection | Feb 28, 2023 |
| 18043413 | MODIFIED BENZOFURAN-CARBOXAMIDES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Merck Sharp & Dohme LLC | TOWNSLEY, SARA ELIZABETH | 1629 | Final Rejection | Feb 28, 2023 |
| 18022570 | PROCESS FOR PREPARING SUGAMMADEX | Werthenstein Biopharma GmbH | BERRY, LAYLA D | 1693 | Final Rejection | Feb 22, 2023 |
| 18041825 | INSULIN RECEPTOR PARTIAL AGONISTS | Merck Sharp & Dohme LLC | CHANDRA, GYAN | 1674 | Non-Final OA | Feb 16, 2023 |
| 18041815 | INSULIN RECEPTOR PARTIAL AGONISTS | Merck Sharp & Dohme LLC | BEANE, RANDALL L | 1654 | Non-Final OA | Feb 16, 2023 |
| 18021369 | CO-STIMULATORY 4-1BBL ECTODOMAIN POLYPEPTIDES FOR IMMUNOMODULATION | Merck Sharp & Dohme LLC | HELLMAN, KRISTINA M | 1654 | Non-Final OA | Feb 14, 2023 |
| 18157686 | THERAPEUTIC AGENTS TARGETING GPR35 | Prometheus Biosciences, Inc. | BORALSKY, LUKE ALAN | 1624 | Non-Final OA | Jan 20, 2023 |
| 18015671 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | Merck Sharp & Dohme LLC | O DELL, DAVID K | 1621 | Non-Final OA | Jan 11, 2023 |
| 18015387 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | Merck Sharp & Dohme LLC | HERNANDEZ, JACKSON J | 1627 | Non-Final OA | Jan 10, 2023 |
| 18015465 | POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR TREATING OR PREVENTING INFLUENZA | Cocrystal Pharma, Inc. | KIFLE, BRUCK | 1624 | Non-Final OA | Jan 10, 2023 |
| 18015364 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | Merck Sharp & Dohme LLC | HERNANDEZ, JACKSON J | 1627 | Non-Final OA | Jan 10, 2023 |
| 18014820 | NOVEL ROR1 ANTIBODY IMMUNOCONJUGATES | Velosbio Inc. | SKOKO III, JOHN JOSEPH | 1643 | Non-Final OA | Jan 06, 2023 |
| 18011856 | HIGH AFFINITY ANTIBODIES TARGETING TAU PHOSPHORYLATED AT SERINE 413 | Merck Sharp Dohme LLC | WANG, CHANG YU | 1675 | Non-Final OA | Dec 21, 2022 |
| 18010888 | ACTRII-ALK4 ANTAGONISTS AND METHODS OF TREATING HEART FAILURE | Acceleron Pharma, Inc. | HOWARD, ZACHARY C | 1674 | Non-Final OA | Dec 16, 2022 |
| 18010416 | SWINE INFLUENZA A VIRUS VACCINE COMPRISING A NUCLEIC ACID CONSTRUCT COMPRISING FIRST, SECOND AND THIRD NUCLEIC ACID SEQUENCES ENCODING DISTINCT NEURAMINIDASE ANTIGENS OF THE VIRUS | Intervet Inc. | BOESEN, AGNIESZKA | 1672 | Non-Final OA | Dec 14, 2022 |
| 18007776 | RIPK1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC | HERNANDEZ, JACKSON J | 1627 | Final Rejection | Dec 02, 2022 |
| 17927222 | PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS | Merck Sharp & Dohme LLC | SAMSELL, RILLA MARIE | 1624 | Non-Final OA | Nov 22, 2022 |
| 18049711 | ANTIBODY DRUG CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS | Ambrx, Inc. | VAN DRUFF, SYDNEY | 1643 | Final Rejection | Oct 26, 2022 |
| 17920919 | DRUG DELIVERY SYSTEM FOR THE DELIVERY OF ANTIVIRAL AGENTS AND CONTRACEPTIVES | Ryan Teller | BECKHARDT, LYNDSEY MARIE | 1613 | Final Rejection | Oct 24, 2022 |
| 17920876 | MODULAR BLENDER AND METHOD OF USING SAME | Merck Sharp & Dohme LLC | SORKIN, DAVID L | 1774 | Non-Final OA | Oct 24, 2022 |
| 17935856 | PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE-CARRIER PROTEIN CONJUGATES | Merck Sharp & Dohme LLC | DEVI, SARVAMANGALA | 1645 | Final Rejection | Sep 27, 2022 |
| 17934396 | PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE-CARRIER PROTEIN CONJUGATES | Merck Sharp & Dohme LLC | DEVI, SARVAMANGALA | 1645 | Non-Final OA | Sep 22, 2022 |
| 17934379 | PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE-CARRIER PROTEIN CONJUGATES | Merck Sharp & Dohme LLC | DEVI, SARVAMANGALA | 1645 | Final Rejection | Sep 22, 2022 |
| 17801471 | HUMAN-LIKE HEAVY CHAIN ANTIBODY VARIABLE DOMAIN (VHH) DISPLAY LIBRARIES | Merck Sharp & Dohme LLC | BOESEN, CHRISTIAN C | 1684 | Non-Final OA | Aug 22, 2022 |
| 17819745 | PD-L1 ANTIBODIES BINDING CANINE PD-L1 | Intervet Inc. | DUFFY, BRADLEY | 1643 | Non-Final OA | Aug 15, 2022 |
| 17798774 | TISSUE TARGETED IMMUNOTOLERANCE WITH PD-1 AGONISTS OR IL-2 MUTEINS | Pandion Operations, Inc. | PATTERSON, SARAH COOPER | 1675 | Non-Final OA | Aug 10, 2022 |
| 17817382 | HPV VACCINE | Merck Sharp & Dohme LLC | ZOU, NIANXIANG | 1671 | Non-Final OA | Aug 04, 2022 |
| 17797238 | VARIANT ACTRIIB PROTEINS AND USES THEREOF | Acceleron Pharma, Inc. | HIBBERT, CATHERINE S | 1658 | Non-Final OA | Aug 03, 2022 |
| 17793583 | DRUG DELIVERY SYSTEM FOR THE DELIVERY OF STEROID TO VITREOUS CHAMBER OF THE EYE | Merck Sharp & Dohme LLC | BABSON, NICOLE PLOURDE | 1619 | Final Rejection | Jul 18, 2022 |
| 17789374 | ARGINASE INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC | WILSON, JERICA KATLYNN | 1621 | Non-Final OA | Jun 27, 2022 |
| 17785750 | NON-INVASIVE CONTINUOUS CAPACITANCE LEVEL DETECTOR | Merck Sharp & Dohme LLC | DEVITO, ALEX T | 2855 | Non-Final OA | Jun 15, 2022 |
| 17785772 | STAPLED OLEFIN CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | Merck Sharp & Dohme LLC | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | Final Rejection | Jun 15, 2022 |
| 17785287 | STAPLED TRIAZOLE CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | Merck Sharp & Dohme LLC | BRADLEY, CHRISTINA | 1654 | Final Rejection | Jun 14, 2022 |
| 17785279 | STAPLED LACTAM CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | Merck Sharp & Dohme LLC | BRADLEY, CHRISTINA | 1654 | Final Rejection | Jun 14, 2022 |
| 17784718 | INDAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES | Merck Sharp & Dohme LLC | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | Non-Final OA | Jun 13, 2022 |
| 17784029 | SINGLE-ARM ACTRIIA AND ACTRIIB HETEROMULTIMERS AND METHODS FOR TREATING PULMONARY HYPERTENSION | Acceleron Pharma, Inc. | HELLMAN, KRISTINA M | 1654 | Non-Final OA | Jun 09, 2022 |
| 17783938 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | Merck Sharp & Dohme LLC | KONOPKA, CATHERINE ANNE | 1635 | Final Rejection | Jun 09, 2022 |
| 17779427 | IN VITRO CELL BASED POTENCY ASSAY | Merck Sharp & Dohme LLC | TAKENAKA, RISA | 1632 | Final Rejection | May 24, 2022 |
| 17664476 | METHODS FOR TREATING CANCER WITH A WEE1 INHIBITOR | Merck Sharp & Dohme LLC | HOWELL, THEODORE R | 1628 | Final Rejection | May 23, 2022 |
| 17642870 | METHODS AND COMPOSITIONS COMPRISING AN ANTI-CTLA4 MONOCLONAL ANTIBODY WITH REDUCED HOST CELL PROTEINS AND INCREASED POLYSORBATE-80 STABILITY | Merck Sharp & Dohme LLC | DUFFY, BRADLEY | 1643 | Non-Final OA | Mar 14, 2022 |
| 17641031 | COMBINATION VACCINE FOR INTRADERMAL ADMINISTRATION | Intervet Inc. | ZEMAN, ROBERT A | 1645 | Non-Final OA | Mar 07, 2022 |
| 17633300 | DRUG DELIVERY SYSTEM FOR THE DELIVERY OF ANTIVIRAL AGENTS | Merck Sharp & Dohme Corp. | VANHORN, ABIGAIL LOUISE | 1636 | Non-Final OA | Feb 07, 2022 |
| 17632151 | System And Method For Determning Status Of Health Of Animals Arriving At A Feed Location | Intervet Inc. | WINSTON III, EDWARD B | 3683 | Final Rejection | Feb 01, 2022 |
| 17618751 | P53 ACTIVATOR PEPTIDOMIMETIC MACROCYCLES | Msd International GmbH (Singapore Branch) | NIEBAUER, RONALD T | 1658 | Non-Final OA | Dec 13, 2021 |
| 17615961 | MDBK IRF3/IRF7 KNOCK OUT MUTANT CELL AND ITS USE FOR VACCINE PRODUCTION | Intervet Inc. | SIFFORD, JEFFREY MARK | 1671 | Non-Final OA | Dec 02, 2021 |
| 17614865 | AN IMMUNOGENIC SEROTYPE 35B PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE AND CONJUGATION PROCESS FOR MAKING THE SAME | Merck Sharp & Dohme LLC | KOLKER, DANIEL E | 1645 | Final Rejection | Nov 29, 2021 |
| 17524511 | ROR1 ANTIBODY IMMUNOCONJUGATES | Velosbio Inc. | MOSELEY II, NELSON B | 1642 | Non-Final OA | Nov 11, 2021 |
| 17482650 | Stable Formulations of Programmed Death Receptor 1 (PD-1) Antibodies and Hyaluronidase Variants and Fragments Thereof and Methods of Use Thereof | Merck Sharp & Dohme LLC | BENAVIDES, JENNIFER ANN | 1675 | Final Rejection | Sep 23, 2021 |
| 17426830 | CANCER TREATMENT WITH ROR1 ANTIBODY IMMUNOCONJUGATES | Velosbio Inc. | PUTTLITZ, KARL J | 1646 | Non-Final OA | Jul 29, 2021 |
| 17386958 | INSULIN-INCRETIN CONJUGATES | Merck Sharp & Dohme Corp. | KOMATSU, LI N | 1658 | Non-Final OA | Jul 28, 2021 |
| 17350321 | LYSINE-SPECIFIC HISTONE DEMETHYLASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | Imago Biosciences, Inc. | CHICKS, ASHLI ARIANA | 1626 | Final Rejection | Jun 17, 2021 |
| 17055100 | DUAL BINDING MOIETY | Harpoon Therapeutics, Inc. | LUNDE, GRACE HENRY | 1641 | Final Rejection | Nov 12, 2020 |
| 17093833 | OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | Merck Sharp & Dohme LLC | PATEL, SAGAR S | 1626 | Non-Final OA | Nov 10, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial